Idiopathic myelofibrosis: Pathogenesis, natural history and management

Blood Reviews

Volumn 11, Issue 4, 1997, Pages 233-242

  Reilly, J T ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANDROGEN; BASIC FIBROBLAST GROWTH FACTOR; CALMODULIN; COLECALCIFEROL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 5; COLLAGEN TYPE 6; EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN; FIBRONECTIN; GAMMA INTERFERON; HYDROXYUREA; LAMININ; MEMBRANE PROTEIN; PLATELET DERIVED GROWTH FACTOR; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; VITRONECTIN;

ADULT; AGED; ANEMIA; BASEMENT MEMBRANE; BLOOD TRANSFUSION; BONE MARROW DISEASE; BONE MARROW TRANSPLANTATION; CHROMOSOME 20Q; CHROMOSOME DELETION; CHROMOSOME DELETION 13; ERYTHROPOIESIS; GENE LOSS; HEMATOPOIESIS; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NEOVASCULARIZATION (PATHOLOGY); PARTIAL TRISOMY; PRIORITY JOURNAL; PROGNOSIS; RADIOTHERAPY; REVIEW; SPLENECTOMY; SURVIVAL TIME; THROMBOCYTHEMIA;

EID: 0031454769     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90022-9     Document Type: Article

References (99)

1. Heuck G. Zwei Fälle von Leukämie mit eigentümlichem Blutresp. Knockenmarksbefund. Virchows Arch 1879; 78: 415-496.
2. Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with myeloproliferative syndrome. Medicine (Baltimore) 1971; 50: 357-420.
3. Silverstein MN. Agnogenic Myeloid Metaplasia. Massachusetts: Publishing Sciences Group Inc., 1975.
4. Rozman C, Giralt M, Feliu E, Rubio D, Cortes M-T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658-2663.
5. Gay S, Gay RE, Prchal JT. Immunohistological studies of bone marrow collagen. In: Berk P, Castro-Malaspina H, Wasserman LR, eds. Myelofibrosis and the Biology of Connective Tissue. New York: Alan R. Liss: 291-306.
6. Apaja-Sarkkinen M, Autio-Harmainen H, Alavaikko M, Risteli J, Risteli L. Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis. Br J Haematol 1986; 63: 571-580.
7. Reilly JT, Brindley L, Kay M et al. Bone marrow and serum connective tissue polypeptides in idiopathic myelofibrosis. Clin Lab Haematol 1995; 17: 35-39.
8. Hasselbalch H, Junker P, Lisse I, Bentsen KD, Risteli L, Risteli J. Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders. Am J Hematol 1986; 23: 101-111.
9. Thiele J, Kuemmel T, Sander C, Fisher R. Ultrastructure of the bone marrow tissue in so-called primary (idiopathic) myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia). 1. Abnormalities of megakaryopoiesis and thrombocytes. J Submicrosc Cytol Pathol 1991; 23: 93-107.
10. Burkhardt R, Bartl R, Beil E, Demmler K, Hoffman E, Kronseder A. Myelofibrosis-osteomyelosclerosis syndrome: review of literature in histomorphology. In: Advances in the Biosciences. Berlin: Dahlem Workshop on Myelofibrosis-Osteomyelosclerosis Syndrome, 1974: 9-54.
11. Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. Prog Clin Biol Res 1984; 154: 427-454.
12. Reilly JT. Pathogenesis of idiopathic myelofibrosis: present status and future directions. Br J Haematol 1994; 88: 1-8.
13. Fava RA, Casey TT, Wilcox J, Pelton RW, Moses HL, Nanney LB. Synthesis of transforming growth factor-β1 by megakaryocytes and its localization to megakaryocyte and platelet α-granules. Blood 1990; 76: 1946-1955.
14. Martyré M-C, Magdelenat H, Calvo F. Interferon-γ in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-β in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1991; 77: 431-435.
15. Zauli G, Visani G, Catani L, Vianelli N, Gugliotta L, Capanis S. Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth β1, produced in normal amount, in patients with essential thrombocythaemia. Br J Haematol 1993; 83: 14-20.
16. Terui T, Niitsu Y, Mahara K et al. The production of transforming growth factor-β in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 1990; 75: 1540-1548.
17. Reilly JT, Barnett D, Dolan G, Forrest P, Eastham J, Smith A. Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. Br J Haematol 1993; 83: 58-62.
18. Johnston JB, Dalal BI, Israels SJ et al. Deposition of transforming growth factor-β in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-β by leukemic cells. Am J Clin Pathol 1995; 103: 574-582.
19. Titius BR, Thiele J, Schaefer H, Kreipe H, Fischer R. Ki-S1 and proliferating cell nuclear antigen expression of bone marrow macrophages. Acta Haematol 1994; 91: 144-149.
20. Rameshwar P, Chang VT, Gascón P. Implication of CD44 in adhesion-mediated overproduction of TGF-β and IL-1 in monocytes from patients with bone marrow fibrosis. Br J Haematol 1996; 96: 22-29.
21. Han ZC, Brière J, Nedellec G et al. Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis. Eur J Haematol 1988; 40: 130-135.
22. Hibbin JAA, Njoku OS, Matutes E, Lewis SM, Goldman JM. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 1984; 57: 495-503.
23. Carlo-Stella C, Cazzola M, Gasner A et al. Effects of recombinant α and γ interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-MK, BFU-E and CFU-GM) from patients with myelofibrosis and myeloid metaplasia. Blood 1987; 70: 1014-1019.
24. Cashman JD, Eaves AC, Raines EW, Ross R, Eaves CJ. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β. Blood 1990; 75: 96-101.
25. + haematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996; 88: 4534-4546.
26. Kimura A, Katoh O, Kuramoto A. Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-β on the growth of human bone marrow fibroblasts. Br J Haematol 1988; 68: 9-12.
27. Eastham JM, Reilly JT, MacNeil S. Raised urinary calmodulin levels in idiopathic myelofibrosis: possible implications for the aetiology of fibrosis. Br J Haematol 1994; 86: 668-670.
28. Dalley A, Smith JM, Reilly JT, MacNeil S. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol 1996; 93: 856-862.
29. Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 1993; 81: 631-638.
30. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987; 8: 95-114.
31. Schelling ME. FGF mediation of coronary angiogenesis. Ann NY Acad Sci 1991; 638: 467-469.
32. Davidson JM, Broadley KN. Manipulation of the wound-healing process with basic fibroblast growth factor. Ann NY Acad Sci 1991; 638: 306-315.
33. Martyré M-C, Le Bousse-Kerdiles M-C, Romquin N et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997; 97: 441-448.
34. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of haematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189-194.
35. Kreipe H, Jaquet K, Felgner J, Radzun H-J, Parwaresch MR. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 1991; 78: 1814-1817.
36. Borgström GH, Knuutila S, Ruutu T, Pakkala A, Lahtinen R, de la Chapelle A. Abnormalities of chromsome 13 in myelofibrosis. Scand J Haematol 1984; 33: 15-21.
37. Miller JB, Testa JR, Lindgren V, Rowley JD. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis. Cancer 1985; 55: 582-591.
38. Demory JL, Dupriez B, Fenaux P et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 1988; 72: 855-859.
39. Reilly JT, Wilson G, Barnett D, Watmore A, Potter A. Karyotype and ras gene mutational analysis in idiopathic myelofibrosis. Br J Haematol 1994; 88: 575-581.
40. Reilly JT, Snowden JA, Spearing R et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997; 98: 96-102.
41. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988; 72: 386-395.
42. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW. Chromsomal studies in 104 patients with polycythemia vera. Mayo Clin Proc 1991; 66: 287-299.
43. Dewald GW, Wright PI. Chromsomal abnormalities in the myeloproliferative disorders. Semin Oncol 1995; 22: 341-454.
44. Morris CM, Cochrane JM, Benjes SM, Crossen PE, Fitzgerald PH. Molecular definition of interstitial deletions of chromosome 13 in leukemic cells. Genes Chromosomes Cancer 1991; 3: 455-460.
45. Pastore C, Nomdedeu J, Volpe G et al. Genetic analysis of chromsomal 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. Genes Chromsomes Cancer 1995; 14: 106-111.
46. Brown AG, Ross FM, Dunne EM, Steel CM, Weir-Thompson EM. Evidence for a new suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. Nat Genet 1993; 3: 67-72.
47. Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature. Leukemia 1991; 5: 214-220.
48. Asimakopoulos FA, Green AR. Deletions of chromsome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 1996; 95: 219-226.
49. Donti E, Tabilio A, Bocchini F et al. Partial trisomy 1q in idiopathic myelofibrosis. Leuk Res 1990; 14: 1035-1040.
50. Rupoli S, Da Lio L, Sisti S et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994; 68: 205-212.
51. Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis: a clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine 1983; 62: 353-371.
52. Visani G, Finelli C, Castelli U et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75: 4-9.
53. Pereira A, Bruguera M, Cervantes F, Rozman C. Liver involvement at diagnosis of primary myelofibrosis. A clinicopathological study of 22 cases. Eur J Haematol 1988; 40: 355-361.
54. Thiele J, Kvasnicka HM, Steinberg T, Zankovich R, Fischer R, Diehl V. Survival in primary (idiopathic) osteomyelofibrosis, so-called agnogenic myeloid metaplasia. Leuk Lymphoma 1992; 6: 389-399.
55. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1988; 70: 397-401.
56. Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol 1983; 54: 70-89.
57. Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018.
58. Iványi JL, Mahunka M, Papp A, Kiss A, Telek B. Prognostic significance of bone marrow reticulin fibres in idiopathic myelofibrosis: evaluation of clinicopathological parameters in a scoring system. Haematologica 1984; 26: 75-86.
59. Silverstein MN, Brown AL, Linman JW Idiopathic myeloid metaplasia: its evolution into acute leukemia. Arch Int Med 1973; 132: 709-712.
60. Marcus RE, Hibbin JA, Matutes E, Whittle N, Waterfield MD, Goldman JM. Megakaryoblastic transformation of myelofibrosis with expression of the c-sis oncogene. Scand J Haematol 1986; 186-193.
61. Garcia S, Miguel A, Miguel A, Linares M, Navarro M, Colomina P. Idiopathic myelofibrosis terminating in erythroleukemia. Am J Hematol 1989; 32: 70-71.
62. Polliak A, Prokocimer M, Matzner Y. Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol 1980; 9: 211-220.
63. Hernández JM, San Miguel JF, González M et al. Development of acute leukaemia after idiopathic myelofibrosis. J Clin Pathol 1992; 45: 427-430.
64. Guardiola P, Espérou H, Cazals-Hatam, D et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 1997; 98: 1004-1009.
65. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98: 1010-1016.
66. Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982; 49: 308-313.
67. Chabannon C, Pegourie B, Sotto J-J, Hollard D. Clinical and hematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia. Nouv Rev Fr Hematol 1990; 32: 165-166.
68. Tefferi A, Silverstein MN. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1994; 86: 893-896.
69. Ammus SS. The role of androgens in the treatment of hematologic disorders. Adv Intern Med 1989; 34: 191-208.
70. Jack FR, Smith SR, Saunders PWG. Idiopathic myelofibrosis: anaemia may respond to low-dose dexamethasone. Br J Haematol 1994; 87: 876-884.
71. Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 1990; 44: 33-38.
72. Manoharan A, Pitney WR. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol 1984; 33: 453-459.
73. Silverstein MN, ReMine WH. Splenectomy in myeloid metaplasia. Blood 1979; 53: 515-518.
74. Barosi G, Ambrosetti A, Buratti A et al. Splenectomy for patients with myelofibrosis and metaplasia: pretreatment variables and outcome prediction. Leukemia 1993; 7: 200-206.
75. Benbassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol 1990; 33: 128-135.
76. Benbassat J, Penchas S, Ligumski M. Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases. Br J Haematol 1979; 42: 207-214.
77. López-Guillermo A, Cervantes F, Bruguera M, Pereira A, Feliu E, Rozman C. Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematol 1991; 85: 184-188.
78. Towell BL, Levine SP. Massive hepatomegaly following splenomegaly for myeloid metaplasia. Case report and review of literature. Am J Med 1987; 82: 371-375.
79. Tefferi A, Barrett SM, Silverstein MN, Nagorney DM. Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. Am J Hematol 1994; 46: 325-328.
80. Leinweber C, Order SE, Calkins AR. Whole-abdominal irradiation for the management of gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Cancer 1991; 68: 1251-1254.
81. Price F, Bell H. Spinal cord compression due to extramedullary hematopoiesis. Successful treatment in a patient with long-standing myelofibrosis. JAMA 1985; 253: 2876-2877.
82. 3 on the relationship between growth and differentiation in HL-60 cells. Leuk Res 1987; 11: 191-196.
83. Munker R, Norman A, Koeffler HP. Vitamin D compounds: effect on clonal proliferation and differentiation of human myeloid cells. J Clin Invest 1986; 78: 424-430.
84. 3 in control of BM collagen deposition. Lancet 1984; I: 78-80.
85. Barosi G. New trends in the treatment of myelofibrosis with myeloid metaplasia. Forum 3.1, 1993: 59-69.
86. Parmeggiani L, Ferrant A, Rodhain J, Michaux JL, Sokal G. Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur J Haematol 1987; 39: 228-232.
87. Barosi G, Liberato LN, Costa A, Ascari E. Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis and myeloid metaplasia. Blutalkohol 1989; 58: 271-274.
88. Gilbert HS. Persistence of remission of myeloid metaplasia after treatment with recombinant interferoncα-2b. Blood 1988; 72: A200.
89. Mohr B, Herrmann R, Hunh D. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. Acta Haematol 1993; 90: 65-70.
90. Aloe Spiriti MA, Latagliata R, Avvisati G et al. Erythropoietin treatment of idiopathic myelofibrosis. Haematologica 1993; 78: 371-373.
91. Frutchman SM, Scigliano E, Wasserman LR. Recombinant erythropoietin (rHuEPO) can be an effective agent in transfusion dependent myelofibrosis. Blood 1990, 76: 271a.
92. Iki S, Yagisawa M, Ohbayashi Y, Sato M, Urabe A. Adverse effect of erythropoietin in myeloproliferative disorders. Lancet 1991; 1: 187.
93. Cazzola M, Ponchio L, Beguin Y et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992; 79: 29-37.
94. Barsoi G, Liberato LN, Guarnone R. Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1993; 83: 365-369.
95. Erslev AJ, Wilson J, Caro J. Erythropoietin titer in anemic, nonuremic patients. J Lab Clin Med; 109: 429-433.
96. Sivera P, Cesano L, Guerrasio A, Camaschella C, Mazza U. Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis. Br J Haematol 1994; 86: 397-398.
97. Tefferi A, Silverstein MN, Plumhoff EA et al. Suramin toxicity and efficay in agnogenic myeloid metaplasia. J Natl Cancer Inst 1993; 85: 1520-1522.
98. Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP. Anagrelide: new drug for treating thrombocytosis. New Engl J Med 1988; 318: 1292-1294.
99. Tefferi A, Silverstein MN, Noël P. Agnogenic myeloid metaplasia. Semin Oncol 1995; 22: 327-333.